First Installation of New Non-Invasive Early Embryo Viability Assessement Test in the EU

Auxogyn, Inc., a company focused on revolutionizing the field of reproductive health, has announced the launch of its Early Embryo Viability Assessment (Eeva) Test in the European Union (EU), with the first installation at the Hewitt Fertility Centre in Liverpool, UK.

The Eeva™ Test is designed to improve in vitro fertilization (IVF) outcomes by providing clinicians and patients with objective information that will enable them to predict embryo viability with a new level of accuracy. Eeva uses intelligent computer vision software to measure key scientifically and clinically validated cell-division parameters from video images. It predicts with high accuracy at the cleavage stage which embryos will likely grow to the blastocyst stage, a critical milestone in embryo development.

“We are proud to be the first clinic in the world to offer the Eeva Test, giving our patients the best chance at a successful embryo implantation,” said Charles Kingsland, lead consultant at the Hewitt Fertility Centre and consultant gynaecologist at the Liverpool Women’s National Health Service Hospital Foundation Trust. “At the Hewitt Fertility Centre, we are committed to doing everything we can, including adopting breakthrough technologies, to improve embryo selection in order to increase a patient’s success of pregnancy while reducing the risks associated with multiple births. By using Eeva, we will be able to help our patients make more informed personal decisions and provide them with the best care possible.”

“Until now, the field of reproductive medicine has been using subjective observation to determine embryo viability. With the commercial launch of Eeva, IVF clinics and their patients will now have access to the first and only noninvasive test that delivers consistent, objective and actionable information to help identify viable embryos and determine which ones offer the greatest potential for transfer,” said Lissa Goldenstein, president and chief executive officer of Auxogyn. “Our goal in developing Eeva is to help infertility patients achieve a successful pregnancy. We expect that the availability of Eeva will help IVF clinics optimize the treatment path for their patients who are undergoing IVF procedures.”